Zhilong Huoxue Tongyu capsule inhibits hypertensive myocardial fibrosis via balancing TGF-β1/Smad3/Erbb4-IR/miR-29b pathway
Abstract Zhilong Huoxue Tongyu capsule (ZL) is wildly used as a Chinese patent medicine for the treatment of cardiovascular diseases. Clinical studies have found that it can significantly improve hypertension and heart failure. However, its precise molecular mechanisms remain incompletely understood...
Saved in:
| Main Authors: | Qiuyu Liu, Dingshan Zhang, Raoqiong Wang, Shihan Sun, Yuanyuan Li, Zhenxun Wan, Yumei Qian, Xinrui Yang, Gang Luo, Mingtai Chen, Mengnan Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-10631-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metabolomics reveals the mechanism of Zhilong Huoxue Tongyu capsule in the treatment of heart failure
by: Li Chen, et al.
Published: (2025-04-01) -
Integrated proteomics analysis and network pharmacology to elucidate the mechanism of Zhilong Huoxue Tongyu Capsule alleviate hypertensive retinopathy in Ang II infusion mice model
by: Jiao Wu, et al.
Published: (2025-05-01) -
Study on the mechanism of Huoxue Lishui compound in treating spontaneous hypertensive rats based on TGF-β1-Smads signaling pathway
by: YANG Shuo, et al.
Published: (2024-08-01) -
Network pharmacology and experimental validation to investigate the mechanism of action of Zhilong Huoxue Tongyu capsule in the prevention and treatment of diabetic cardiomyopathy.
by: Fang Yang, et al.
Published: (2025-01-01) -
The mechanism of Ningxin-Tongyu-Zishen formula regulating probdnf/mbdnf balance through PAI-1/tPA signaling pathway in the treatment of premature ovarian insufficiency
by: Jiawen Ma, et al.
Published: (2025-08-01)